Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients
- PMID: 38961386
- PMCID: PMC11223384
- DOI: 10.1186/s12888-024-05933-7
Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients
Abstract
Objectives: Electroconvulsive therapy (ECT) is one of the most effective treatments in mood disorders, mainly in major depressive episode (MDE) in the context of either unipolar (MDD) or bipolar disorder (BD). However, ECT remains a neglected and underused treatment. Older people are at high risk patients for the development of adverse drug reactions. In this context, we sought to determine the duration of MDEs and the number of lines of treatment before the initiation of ECT in patients aged 65 years or over according to the presence or absence of first-line indications for using ECT from international guidelines.
Methods: In this multicenter, retrospective study including patients aged 65 years or over with MDEs in MDD or BD who have been treated with ECT for MDEs, data on the duration of MDEs and the number of lines of treatment received before ECT were collected. The reasons for using ECT, specifically first-line indications (suicidality, urgency, presence of catatonic and psychotic features, previous ECT response, patient preference) were recorded. Statistical comparisons between groups used standard statistical tests.
Results: We identified 335 patients. The mean duration of MDEs before ECT was about 9 months. It was significantly shorter in BD than in MDD- about 7 and 10 months, respectively. The co-occurrence of chronic medical disease increased the duration before ECT in the MDD group. The presence of first-line indications for using ECT from guidelines did not reduce the duration of MDEs before ECT, except where there was a previous response to ECT. The first-line indications reduced the number of lines of treatment before starting ECT.
Conclusion: Even if ECT seems to be a key treatment in the elderly population due to its efficacity and safety for MDEs, the delay before this treatment is still too long.
Keywords: Bipolar disorder; ECT; Geriatric patients; Major depressive disorder; Mood disorder.
© 2024. The Author(s).
Conflict of interest statement
Pr. Samalin has received personal fees and/or non-financial support from Janssen, Lundbeck and Otsuka.
Pr Yrondi has received speaker's honoraria (AstraZeneca, Janssen, Lundbeck, Otsuka, Servier), carried out clinical studies in relation to the.
development of a medicine (Janssen) unrelated to this work.
Dr Genty has received speaker's honoraria from Servier.
Pr Sauvaget has received personal fees and/or non-financial support from Janssen, and Lundbeck.
Pr Poulet has received personal fees and/or non-financial support from Janssen, EISAI, Otsuka and Lundbeck.
Dr Holtzmann has received personal fees and/or non-financial support from Janssen and Lundbeck.
Pr Richieri has received speaker's honoraria from Otsuka and Janssen-Cilag. She has served on advisory boards for LivaNova.
Pr El-Hage has received speaker's honoraria from CHUGAI, EISAI, Lundbeck, Janssen-Cilag, and UCB unrelated to this work. He served on advisory boards for Janssen-Cilag and Lundbeck.
Pr Aouizerate has received speaker's honoraria from Lundbeck,Lilly, and Janssen-Cilag. He has served on advisory boards for Janssen-Cilag.
Pr Haffen acted in advisory capacities, carried out clinical studies inrelation to the development of a medicine, received personal researches,studies or travel allowance, gave presentations at meetings, and received remuneration for input from the following pharmaceutical organisations: AstraZeneca, BMS, Cellgene, Euthérapie—Servier, Janssen, Elli Lilly, Lundbeck, LivaNova, Otsuka, Pfizer, Sanofi.
Pr Llorca has received grants, honoraria, or consulting fees fromESAI, Gedeon Richeter, Janssen, Lundbeck, Otsuka and Sanofi.
No potential conflict of interest was reported by the other authors.
Figures
Similar articles
-
Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode.J Affect Disord. 2020 Mar 1;264:318-323. doi: 10.1016/j.jad.2020.01.004. Epub 2020 Jan 7. J Affect Disord. 2020. PMID: 32056767
-
Bi-temporal electroconvulsive therapy efficacy in bipolar and unipolar depression: A retrospective comparison.Asian J Psychiatr. 2021 Jan;55:102503. doi: 10.1016/j.ajp.2020.102503. Epub 2020 Nov 30. Asian J Psychiatr. 2021. PMID: 33296865
-
The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features.Curr Neuropharmacol. 2017 Apr;15(3):359-371. doi: 10.2174/1570159X14666161017233642. Curr Neuropharmacol. 2017. PMID: 28503107 Free PMC article.
-
Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.J Affect Disord. 2025 Feb 15;371:45-53. doi: 10.1016/j.jad.2024.11.034. Epub 2024 Nov 14. J Affect Disord. 2025. PMID: 39549887 Review.
-
The effectiveness of electroconvulsive therapy (ECT) for people with bipolar disorder: is there a specific role?Expert Rev Neurother. 2025 Apr;25(4):381-388. doi: 10.1080/14737175.2025.2470979. Epub 2025 Feb 26. Expert Rev Neurother. 2025. PMID: 40007434 Review.
Cited by
-
Age-Dependent Efficacy of Electroconvulsive Therapy in Depression: A Longitudinal Study of Symptom Trajectories and Treatment Predictions.Brain Behav. 2025 Apr;15(4):e70487. doi: 10.1002/brb3.70487. Brain Behav. 2025. PMID: 40259691 Free PMC article.
-
Electroconvulsive therapy modulates the interplay between depressive symptoms in difficult-to-treat depression: A longitudinal network analysis.Eur Psychiatry. 2025 Jun 16;68(1):e84. doi: 10.1192/j.eurpsy.2025.10052. Eur Psychiatry. 2025. PMID: 40518720 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical